memantine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with memantine prevented the chorea movement and the progression of Huntington's disease." | 8.31 | Memantine administration prevented chorea movement in Huntington's disease: a case report. ( Hirano, M; Ikegawa, A; Kusunoki, S; Mitsui, Y; Nagai, Y; Oda, I; Saigoh, K; Samukawa, M; Yamagishi, Y; Yoshikawa, K, 2023) |
| " Treatment with memantine prevented the chorea movement and the progression of Huntington's disease." | 4.31 | Memantine administration prevented chorea movement in Huntington's disease: a case report. ( Hirano, M; Ikegawa, A; Kusunoki, S; Mitsui, Y; Nagai, Y; Oda, I; Saigoh, K; Samukawa, M; Yamagishi, Y; Yoshikawa, K, 2023) |
| " We hypothesized that hyper-excitability in Huntington disease (HD) disrupts the coordinated structural and functional connectivity, and treatment with memantine helps to reduce excitotoxicity and normalize the connectivity." | 3.88 | Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model. ( Chang, WT; Chuang, KH; Garcia-Miralles, M; Koh, KB; Pouladi, MA; Puspitasari, F; Tan, LJ; Tay, HC; Yeow, LY, 2018) |
| "We described a 32-year-old woman with Huntington's disease (HD) who presented with severe chorea, psychosis and cognitive abnormalities." | 1.33 | Clinical experience with risperidone and memantine in the treatment of Huntington's disease. ( Cakir, A; Cankurtaran, ES; Ozalp, E; Soygur, H, 2006) |
| "Huntington's disease has an increase in the activated calpain, which is enhanced by the NMDA receptor activation." | 1.33 | Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. ( Chu, K; Jung, KH; Kang, L; Kim, M; Ko, SY; Lee, ST; Park, JE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Radulović, S | 1 |
| Sunkara, S | 1 |
| Maurer, C | 1 |
| Leitinger, G | 1 |
| Saigoh, K | 1 |
| Hirano, M | 1 |
| Mitsui, Y | 1 |
| Oda, I | 1 |
| Ikegawa, A | 1 |
| Samukawa, M | 1 |
| Yoshikawa, K | 1 |
| Yamagishi, Y | 1 |
| Kusunoki, S | 1 |
| Nagai, Y | 1 |
| Chang, WT | 1 |
| Puspitasari, F | 1 |
| Garcia-Miralles, M | 1 |
| Yeow, LY | 1 |
| Tay, HC | 1 |
| Koh, KB | 1 |
| Tan, LJ | 1 |
| Pouladi, MA | 1 |
| Chuang, KH | 1 |
| Dau, A | 1 |
| Gladding, CM | 2 |
| Sepers, MD | 2 |
| Raymond, LA | 2 |
| Carter, RL | 1 |
| Chen, Y | 1 |
| Kunkanjanawan, T | 1 |
| Xu, Y | 1 |
| Moran, SP | 1 |
| Putkhao, K | 1 |
| Yang, J | 1 |
| Huang, AH | 1 |
| Parnpai, R | 1 |
| Chan, AW | 1 |
| Mahfooz, K | 1 |
| Marco, S | 1 |
| Martínez-Turrillas, R | 1 |
| Raja, MK | 1 |
| Pérez-Otaño, I | 1 |
| Wesseling, JF | 1 |
| Anitha, M | 1 |
| Nandhu, MS | 1 |
| Anju, TR | 1 |
| Jes, P | 1 |
| Paulose, CS | 1 |
| Hjermind, LE | 1 |
| Law, I | 1 |
| Jønch, A | 1 |
| Stokholm, J | 1 |
| Nielsen, JE | 1 |
| Milnerwood, AJ | 1 |
| Kaufman, AM | 1 |
| Zhang, L | 1 |
| Wang, L | 1 |
| Fan, J | 1 |
| Coquinco, A | 1 |
| Qiao, JY | 1 |
| Lee, H | 1 |
| Wang, YT | 1 |
| Cynader, M | 1 |
| Danysz, W | 1 |
| Beister, A | 1 |
| Kraus, P | 1 |
| Kuhn, W | 1 |
| Dose, M | 1 |
| Weindl, A | 1 |
| Gerlach, M | 1 |
| Cankurtaran, ES | 1 |
| Ozalp, E | 1 |
| Soygur, H | 1 |
| Cakir, A | 1 |
| Lee, ST | 1 |
| Chu, K | 1 |
| Park, JE | 1 |
| Kang, L | 1 |
| Ko, SY | 1 |
| Jung, KH | 1 |
| Kim, M | 1 |
| Wu, J | 1 |
| Tang, T | 1 |
| Bezprozvanny, I | 1 |
| Ondo, WG | 1 |
| Mejia, NI | 1 |
| Hunter, CB | 1 |
1 review available for memantine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Humans; Huntington Disease; Levodo | 2021 |
2 trials available for memantine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.
Topics: Activities of Daily Living; Adolescent; Adult; Disease Progression; Excitatory Amino Acid Antagonist | 2004 |
A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Female; Humans; Huntington Disease; Male; Memantine; | 2007 |
12 other studies available for memantine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Memantine administration prevented chorea movement in Huntington's disease: a case report.
Topics: Aged; Alzheimer Disease; Chorea; Dyskinesias; Female; Humans; Huntington Disease; Iofetamine; Male; | 2023 |
Connectomic imaging reveals Huntington-related pathological and pharmaceutical effects in a mouse model.
Topics: Animals; Axons; Behavior, Animal; Cognition; Connectome; Disease Models, Animal; Electric Stimulatio | 2018 |
Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice.
Topics: Animals; Calcium Signaling; Calpain; Corpus Striatum; CREB-Binding Protein; Excitatory Amino Acid An | 2014 |
Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells.
Topics: Animals; Antiparkinson Agents; Apoptosis; Cells, Cultured; GABAergic Neurons; Haplorhini; Huntingtin | 2014 |
GluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Huntington Disease; Memantine; Mice | 2016 |
Targeting glutamate mediated excitotoxicity in Huntington's disease: neural progenitors and partial glutamate antagonist--memantine.
Topics: Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Memantine; Receptors, Glutamate; Stem | 2011 |
Huntington's disease: effect of memantine on FDG-PET brain metabolism?
Topics: Adult; Brain; Disease Progression; Excitatory Amino Acid Antagonists; Glucose; Humans; Huntington Di | 2011 |
Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Topics: Animals; Apoptosis; Cerebral Cortex; Coculture Techniques; Corpus Striatum; Disease Models, Animal; | 2012 |
Society of neuroscience-33rd annual meeting: metabotropic glutamate receptors.
Topics: Animals; Antiparkinson Agents; Anxiety; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Hunting | 2004 |
Clinical experience with risperidone and memantine in the treatment of Huntington's disease.
Topics: Adult; Cognition; Dopamine Antagonists; Drug Therapy, Combination; Excitatory Amino Acid Antagonists | 2006 |
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Calpain; Cell Death; Corpus Striatum; Disease Models, Animal | 2006 |
Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.
Topics: Amines; Animals; Apoptosis; Cells, Cultured; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Anta | 2006 |